Non-peptidic Cruzain Inhibitors with Trypanocidal Activity Discovered by Virtual Screening and In Vitro Assay

PLoS Neglected Tropical Diseases

Volumn 7, Issue 8, 2013, Pages

  Wiggers, Helton J ^a,b   Rocha, Josmar R ^b   Fernandes, William B ^b,c   Sesti Costa, Renata ^b   Carneiro, Zumira A ^b   Cheleski, Juliana ^b   da Silva, Albérico B F ^b   Juliano, Luiz ^d   Cezari, Maria H S ^d   Silva, João S ^b   McKerrow, James H ^c   Montanari, Carlos A ^a,b  

^a FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; CRUZAIN INHIBITOR; LIGAND; NEQUIMED 176; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHAGAS DISEASE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DOSE RESPONSE; DRUG SCREENING; ENZYME ASSAY; IC 50; MOUSE; NONHUMAN; TRYPANOSOMA CRUZI;

EID: 84883431785     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002370     Document Type: Article

References (57)

1. Clayton J, (2010) Chagas disease 101. Nature 465: S4-S5.
2. Coura JR, Vinas PA, (2010) Chagas disease: a new worldwide challenge. Nature 465: S6-S7.
3. World Health Organization (2010) Chagas disease (American trypanosomiasis). Available: http://www.who.int/mediacentre/factsheets/fs340/en/. Accessed 17 July 2013.
4. Vermelho AB, Melo ACN, Soares RA, Alviano DS, Souza EP, et al. (2007) Trypanosoma cruzi Peptidases: An Overview. The Open Parasitology Journal 4: 120-131.
5. Urbina JA, (2010) Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Tropica 115: 55-68.
6. Gillmor SA, Craik CS, Fletterick RJ, (1997) Structural determinants of specificity in the cysteine protease cruzain. Protein Science 6: 1603-1611.
7. McKerrow JH, Doyle PS, Engel JC, Podust LM, Robertson S, et al. (2009) Two approaches to discovering and developing new drugs for Chagas disease. Memórias do Instituto Osvaldo Cruz 101: 263-269.
8. Powers JC, Asgian JL, Ekici ÖD, James KE, (2002) Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases. Chemical Reviews 102: 4639-4750.
9. Götz MG, Caffrey CR, Hansell E, McKerrow JH, Powers JC, (2004) Peptidyl allyl sulfones: a new class of inhibitors for clan CA cysteine proteases. Bioorganic & Medicinal Chemistry 12: 5203-5211.
10. Scheidt KA, Roush WR, McKerrow JH, Selzer PM, Hansell E, et al. (1998) Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors. Bioorganic & Medicinal Chemistry 6: 2477-2494.
11. Ferreira RS, Simeonov A, Jadhav A, Eidam O, Mott BT, et al. (2010) Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors. Journal of Medicinal Chemistry 53: 4891-4905.
12. Schirmeister T, Kaeppler U, (2003) Non-Peptidic Inhibitors of Cysteine Proteases. Mini-Reviews in Medicinal Chemistry 3: 361-373.
13. Kerr ID, Lee JH, Farady CJ, Marion R, Rickert M, et al. (2009) Vinyl Sulfones as Antiparasitic Agents and a Structural Basis for Drug Design. Journal of Biological Chemistry 284: 25697-25703.
14. Chen YT, Brinen LS, Kerr ID, Hansell E, Doyle PS, et al. (2010) In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. PLoS Neglected Tropical Diseases 4: e825.
15. Irwin JJ, Shoichet BK, (2005) ZINC- A free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling 45: 177-182.
16. Cavasotto CN, Orry AJ, (2007) Ligand docking and structure-based virtual screening in drug discovery. Current Topics in Medicinal Chemistry 7: 1006-1014.
17. Douguet D, (2008) Ligand-based approaches in virtual screening. Current Computer-Aided Drug Design 4: 180-190.
18. FILTER, version 2.0.2; Openeye Scientific Software Inc: Santa Fe, NM, USA, 2007.
19. Boström J, Greenwood JR, Gottfries J, (2003) Assessing the performance of OMEGA with respect to retrieving bioactive conformations. Journal of Molecular Graphics and Modelling 21: 449-462.
20. Hawkins PCD, Skillman AG, Warren GL, Ellingson BA, Stahl MT, (2010) Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database. Journal of Chemical Information and Modeling 50: 572-584.
21. OMEGA, version 2.3.2; Openeye Scientific Software: Santa Fe, NM, USA, 2010.
22. Grant JA, Gallardo MA, Pickup BT, (1996) A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape. Journal of Computational Chemistry 17: 1653-1666.
23. ROCS, version 2.4.1; Openeye Scientific Software: Santa Fe, NM, USA, 2010.
24. Openeye Scientific Software (2010) ROCS user guide; Santa Fe, NM; USA.
25. Wiggers HJ, Rocha JR, Cheleski J, Montanari CA, (2011) Integration of ligand- and target-based virtual screening for the discovery of cruzain inhibitors. Molecular Informatics 30: 365-378.
26. McGann M, (2011) FRED Pose Prediction and Virtual Screening Accuracy. Journal of Chemical Information and Modeling 51: 578-596.
27. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. Journal of Medicinal Chemistry 47: 1739-1749.
28. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, et al. (2004) Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. Journal of Medicinal Chemistry 47: 1750-1759.
29. Eakin AE, Mills AA, Harth G, McKerrow JH, Craik CS, (1992) The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi. Journal of Biological Chemistry 267: 7411-7420.
30. Barrett AJ, Kembhavi AA, Brown MA, (1982) L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins, B, H and L. Biochemical Journal 201: 189-198.
31. Systat Software (2006) SigmaPlot, version 10.0. San Jose: Systat Software, Inc.
32. Lee GM, Balouch E, Goetz DH, Lazic A, McKerrow JH, et al. (2012) Mapping Inhibitor Binding Modes on an Active Cysteine Protease via Nuclear Magnetic Resonance Spectroscopy. Biochemistry 51: 10087-10098.
33. Holton J, Alber T, (2004) Automated protein crystal structure determination using elves. Proceedings of the National Academy of Sciences of the United States of America 101: 1537-1542.
34. Leslie AW, Powell H (2007) In: Read R, Sussman J, editors. Evolving Methods for Macromolecular Crystallography. Volume 245. Netherlands: Springer. pp. 41-51.
35. Evans P, (2006) Scaling and assessment of data quality. Acta Crystallographica Section D 62: 72-82.
36. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. Journal of Applied Crystallography 40: 658-674.
37. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallographica Section D 66: 213-221.
38. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallographica Section D 60: 2126-2132.
39. Chen VB, Arendall WB III, Headd JJ, Keedy DA, Immormino RM, et al. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallographica Section D 66: 12-21.
40. Brener Z, (1962) Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Revista do Instituto de Medicina Tropical de Sao Paulo 4: 389-396.
41. Carvalho I, Andrade P, Campo VL, Guedes PMM, Sesti-Costa R, et al. (2010) 'Click chemistry' synthesis of a library of 1,2,3-triazole-substituted galactose derivatives and their evaluation against Trypanosoma cruzi and its cell surface trans-sialidase. Bioorganic & Medicinal Chemistry 18: 2412-2427.
42. Silva JJN, Pavanelli WRr, Gutierrez FRS, Lima FCA, Silva ArBF, et al. (2008) Complexation of the anti-Trypanosoma cruzi Drug Benznidazole Improves Solubility and Efficacy. Journal of Medicinal Chemistry 51: 4104-4114.
43. McNicholas S, Potterton E, Wilson KS, Noble MEM, (2011) Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallographica Section D 67: 386-394.
44. Ferreira RS, Bryant C, Ang KKH, McKerrow JH, Shoichet BK, et al. (2009) Divergent modes of enzyme inhibition in a homologous structure-activity series. Journal of Medicinal Chemistry 52: 5005-5008.
45. Freitas RF, Oprea TI, Montanari CA, (2008) 2D QSAR and similarity studies on cruzain inhibitors aimed at improving selectivity over cathepsin L. Bioorganic & Medicinal Chemistry 16: 838-853.
46. Malvezzi A, de Rezende L, do Amaral AT, (2009) Pharmacopore model of cruzain inhibitors. QSAR and Combinatorial Science 28: 781-784.
47. Kurczab R, Nowak M, Chilmonczyk Z, Sylte I, Bojarski AJ, (2010) The development and validation of a novel virtual screening cascade protocol to identify potential serotonin 5-HT7R antagonists. Bioorganic & Medicinal Chemistry Letters 20: 2465-2468.
48. Lakshmi PJ, Kumar B, Nayana RS, Mohan MS, Bolligarla R, et al. (2009) Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorganic & Medicinal Chemistry 17: 6040-6047.
49. Perez-Pineiro R, Burgos A, Jones DC, Andrew LC, Rodriguez H, et al. (2009) Development of a Novel Virtual Screening Cascade Protocol to Identify Potential Trypanothione Reductase Inhibitors. Journal of Medicinal Chemistry 52: 1670-1680.
50. Hubbard R, (2008) Fragment approaches in structure-based drug discovery. Journal of Synchrotron Radiation 15: 227-230.
51. Orita M, Ohno K, Warizaya M, Amano Y, Niimi T. (2011) In: Lawrence CK, editor. Methods in Enzymology. Volume 493. San Diego: Academic Press. pp. 383-419.
52. Schulz MN, Landström J, Bright K, Hubbard RE, (2011) Design of a Fragment Library that maximally represents available chemical space. Journal of Computer-Aided Molecular Design 25: 611-620.
53. Hopkins AL, Groom CR, Alex A, (2004) Ligand efficiency: A useful metric for lead selection. Drug Discovery Today 9: 430-431.
54. Siegal G, Ab E, Schultz J, (2007) Integration of fragment screening and library design. Drug Discovery Today 12: 1032-1039.
55. Brak K, Kerr ID, Barrett KT, Fuchi N, Debnath M, et al. (2010) Nonpeptidic Tetrafluorophenoxymethyl Ketone Cruzain Inhibitors as Promising New Leads for Chagas Disease Chemotherapy. Journal of Medicinal Chemistry 53: 1763-1773.
56. Burgess JL, Callahan JF, Wan Z. USA Patent WO2003029242-A, April 10; 2003, 32 pages.
57. Doyle PS, Zhou YM, Hsieh I, Greenbaum DC, McKerrow JH, et al. (2011) The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion. PLoS Pathogens 7: e1002139.